Pharmaceutical Executive
March 01, 2005
World News
Pharma companies in Europe believe that it already takes too long for new medicines to reach patients. Separate bodies for efficacy and safety will lead to further delays.
March 01, 2005
Special Reports
If the Aspen model works, it could change the model for the developing world. Research-based companies could focus on R&D, and leave the manufacturing to generic companies.
March 01, 2005
Features
The use of a CUI leads development efforts to explre the most valuable region of treatment - not necessarily the the most efficacious.
March 01, 2005
From the Editor
In the drug safety debate, we're hearing plenty of potential solutions. They're smart and advance desirable goals. There's just one thing wrong with them: They don't solve the problem.
March 01, 2005
Features
In an ideal world, an anti-counterfeit solution would provide protection throughout the supply chain, allow for easy product identification by physicians, pharmacists, and patients, be easily implemented without ongoing costs-and improve brand image and marketability while it's at it. Yet most current anti-counterfeiting measures involve packaging technologies such as holograms, inks, bar codes and radio frequency ID (RFID) that, although useful, cannot ensure the integrity of the pharmaceutical supply chain, because drugs do not remain in their original packaging. Legitimate repackaging regularly occurs in the pharmacy and elsewhere, and authentic packaging-recycled or stolen-can contain adulterated, counterfeited drugs.
March 01, 2005
Washington Report
Should policy makers expect 90 percent of seniors to enroll in PDPs, or will 75 percent be enough? Will the program have to keep costs down to $400 billion a year, or will spending be linked to savings elsewhere?
March 01, 2005
Pharm Exec talks to the newly appointed leaders of the industry's most influential advocacy organizations.